Delapril

Identification

Summary

Delapril is an ACE inhibitor indicated in the treatment of essential hypertension.

Generic Name

Delapril

DrugBank Accession Number

DB13312

Background

Not Available

Type

Small Molecule

Groups

Investigational

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Delapril (DB13312)

×

Close

Weight

Average: 452.551
Monoisotopic: 452.231122138

Chemical Formula

C₂₆H₃₂N₂O₅

Synonyms

• Delapril

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Treatment of	Congestive heart failure (chf)		••••••••••••			••••••
Used in combination to treat	High blood pressure (hypertension)	Combination Product in combination with: Manidipine (DB09238)	••••••••••••		•••••••••• ••••••• •• •••••••••••	••••••
Used in combination to treat	High blood pressure (hypertension)	Combination Product in combination with: Indapamide (DB00808)	••••••••••••		•••••••••• ••••••• •• •••••••••••	••••••
Treatment of	High blood pressure (hypertension)		••••••••••••			••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abaloparatide	Abaloparatide may increase the hypotensive activities of Delapril.
Acebutolol	Acebutolol may increase the hypotensive activities of Delapril.
Aceclofenac	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Delapril.
Acemetacin	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acemetacin is combined with Delapril.
Acetylsalicylic acid	The therapeutic efficacy of Delapril can be decreased when used in combination with Acetylsalicylic acid.

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Delapril hydrochloride	2SMM3M5ZMH	83435-67-0	FDJCVHVKXFIEPJ-JCNFZFLDSA-N

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
DELAPRIDE	Delapril (30 MG) + Indapamide (2.5 MG)	Tablet	Oral	Promedica S.R.L.	2014-07-08	2023-01-12
DELAPRIDE	Delapril (30 MG) + Indapamide (1.25 MG)	Tablet	Oral	Promedica S.R.L.	2014-07-08	Not applicable
DINAPRES	Delapril (30 MG) + Indapamide (2.5 MG)	Tablet	Oral	Master Pharma S.R.L.	2014-07-08	2023-01-12
DINAPRES	Delapril (30 MG) + Indapamide (1.25 MG)	Tablet	Oral	Master Pharma S.R.L.	2014-07-08	Not applicable
FRAGOR	Delapril (30 MG) + Manidipine (10 MG)	Tablet	Oral	Chiesi Farmaceutici S.P.A.	2014-07-08	2021-06-01

Categories

ATC Codes

C09AA12 — Delapril

• C09AA — ACE inhibitors, plain
• C09A — ACE INHIBITORS, PLAIN
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

C09BB12 — Delapril and manidipine

• C09BB — ACE inhibitors and calcium channel blockers
• C09B — ACE INHIBITORS, COMBINATIONS
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

C09BA12 — Delapril and diuretics

• C09BA — ACE inhibitors and diuretics
• C09B — ACE INHIBITORS, COMBINATIONS
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

Drug Categories

• ACE Inhibitors and Calcium Channel Blockers
• ACE Inhibitors and Diuretics
• Agents Acting on the Renin-Angiotensin System
• Agents causing angioedema
• Agents causing hyperkalemia
• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents
• Cardiovascular Agents
• Enzyme Inhibitors
• Indenes
• Protease Inhibitors

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as peptoid-peptide hybrids. These are compounds containing a peptoid-peptide backbone, which consists alternating amino acid and n-substituted amino acids linked to each other by a peptide bond.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Peptidomimetics

Sub Class

Peptoid-peptide hybrids

Direct Parent

Peptoid-peptide hybrids

Alternative Parents

Dipeptides / N-acyl-alpha amino acids / Alpha amino acid esters / Alpha amino acid amides / Alanine and derivatives / Indanes / Fatty acid esters / Aralkylamines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Amino acids / Carboxylic acid esters / Dialkylamines / Carboxylic acids / Organopnictogen compounds / Hydrocarbon derivatives / Organic oxides / Carbonyl compounds

show 9 more

Substituents

Alanine or derivatives / Alpha-amino acid amide / Alpha-amino acid ester / Alpha-amino acid or derivatives / Alpha-dipeptide / Amine / Amino acid / Amino acid or derivatives / Aralkylamine / Aromatic homopolycyclic compound / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Dicarboxylic acid or derivatives / Fatty acid ester / Fatty acyl / Hydrocarbon derivative / Indane / Monocyclic benzene moiety / N-acyl-alpha amino acid or derivatives / N-acyl-alpha-amino acid / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Peptoid/peptide hybrid / Secondary aliphatic amine / Secondary amine / Tertiary carboxylic acid amide

show 24 more

Molecular Framework

Aromatic homopolycyclic compounds

External Descriptors

Not Available

Affected organisms

Not Available

Chemical Identifiers

UNII

W77UAL9THI

CAS number

83435-66-9

InChI Key

WOUOLAUOZXOLJQ-MBSDFSHPSA-N

InChI

InChI=1S/C26H32N2O5/c1-3-33-26(32)23(14-13-19-9-5-4-6-10-19)27-18(2)25(31)28(17-24(29)30)22-15-20-11-7-8-12-21(20)16-22/h4-12,18,22-23,27H,3,13-17H2,1-2H3,(H,29,30)/t18-,23-/m0/s1

IUPAC Name

2-[(2S)-N-(2,3-dihydro-1H-inden-2-yl)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanamido]acetic acid

SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=C(C1)C=CC=C2

References

General References

1. AIFA Product Information: Delaket (delapril hydrochloride) oral tablets [Link]
2. AIFA Product Information: Delapride (delapril/indapamide) oral tablets [Link]
3. AIFA Product Information: Fragor (delapril hydrochloride/manidipine hydrochloride) oral tablets [Link]

External Links

ChemSpider

4514931

ChEBI

135735

ChEMBL

CHEMBL589583

ZINC

ZINC000003794599

Wikipedia

Delapril

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
3	Completed	Diagnostic	Type 2 Diabetes Mellitus	1
3	Completed	Treatment	Hypertension	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Tablet	Oral
Tablet	Oral	15 MG
Tablet	Oral	30 MG
Tablet	Oral

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00537 mg/mL	ALOGPS
logP	1.69	ALOGPS
logP	2.17	Chemaxon
logS	-4.9	ALOGPS
pKa (Strongest Acidic)	3.82	Chemaxon
pKa (Strongest Basic)	5.21	Chemaxon
Physiological Charge	-1	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	95.94 Å2	Chemaxon
Rotatable Bond Count	12	Chemaxon
Refractivity	124.64 m3·mol-1	Chemaxon
Polarizability	49.42 Å3	Chemaxon
Number of Rings	3	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	Yes	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0udi-0324900000-5e05e85cc850ff3ba0bd
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0udi-1118900000-72956971bedf219fcba1
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0006-8955400000-3e411ce6d16dda416bd5
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-03xr-0920100000-fe4cf1c30e548dc664f2
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-02tc-4921000000-6b948a3917db12d96790
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-03di-1912000000-7c7001853bfd69c43748
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	197.37524	predicted	DeepCCS 1.0 (2019)
[M+H]+	199.77083	predicted	DeepCCS 1.0 (2019)
[M+Na]+	205.68388	predicted	DeepCCS 1.0 (2019)

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 23, 2017 20:39 / Updated at June 02, 2021 20:04